Search Clinical Trials
Below please find a list of studies actively recruiting volunteers at one of the following GHUCCTS institutions: Georgetown University, Howard University, MedStar Health Research Institute, or Washington DC VA Medical Center. Please enter your search criteria below to help find a study for you. If you have any questions, please email us or call us at 301-560-2963.
Sponsor Condition of Interest |
---|
Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients
Johns Hopkins University
HIV Infection
HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from
an HIV+ deceased donor will be followed to determine the safety and efficacy of this
practice. Some HIV+ individuals who receive a solid organ transplant from HIV-uninfected
(HIV-)... expand
HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from an HIV+ deceased donor will be followed to determine the safety and efficacy of this practice. Some HIV+ individuals who receive a solid organ transplant from HIV-uninfected (HIV-) donors will also be followed. Type: Observational Start Date: Nov 2015 |
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel,...
National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
HER2-Negative Breast Carcinoma
Hormone Receptor-Positive Breast Carcinoma
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual
chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh
(MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with... expand
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. Type: Interventional Start Date: Nov 2023 |
ExoLuminate Study for Early Detection of Pancreatic Cancer
Biological Dynamics
Pancreas Cancer
Exosomes
Extracellular Vesicles
Pancreatic Neoplasms
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer
in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma
(PDAC).
Those with elevated risk for PDAC can include individuals with intraductal papillary... expand
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance. Type: Observational [Patient Registry] Start Date: Dec 2022 |
CONVERGE Post-Approval Study (PAS)
AtriCure, Inc.
Chronic Atrial Fibrillation
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and
long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided
Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing
persistent... expand
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD. Type: Interventional Start Date: Apr 2022 |
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
Target ALS Foundation, Inc.
Amyotrophic Lateral Sclerosis
Movement Disorders
Degenerative Disorder
Motor Neuron Disease
Brief Summary: The goal of the study is to generate a biorepository of longitudinal blood
(plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal
clinical information that are made available to the research community. To accomplish these... expand
Brief Summary: The goal of the study is to generate a biorepository of longitudinal blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 200 Amyotrophic Lateral Sclerosis (ALS) patients and 80 healthy controls from multiple sites, over a 5 year time frame. Additionally, speech measures will be collected on weekly basis at home for all participants. The measurements are performed using a speech recording application installed on their personal device. For a subset of both ALS and healthy participants, we will also collect at-home vital capacity on a weekly basis. It is expected that increased frequency data sampling of these outcome measures will help in better tracking of disease progression. Biofluids and clinical information are collected over a 20-month time frame for each individual enrolled in the research study. ALS participants will be coming to clinic for 5 study visits with a 4-month interval between visits. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies. Type: Observational [Patient Registry] Start Date: Jan 2021 |
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal...
ECOG-ACRIN Cancer Research Group
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
This phase III trial studies how well the addition of radiotherapy to the usual treatment
(chemotherapy) works compared to the usual treatment alone in treating patients with
esophageal and gastric cancer that has spread to a limited number of other places in the body
(oligometastatic... expand
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer. Type: Interventional Start Date: May 2020 |
Promotion of Weight Management
VA Office of Research and Development
Overweight
The identification of intermittent fasting as an alternative method to traditional weight
maintenance protocols could have a significant impact on preventing body weight regain common
after successful weight loss, and potentially lead to a reduction in pharmaceutical and
clinical... expand
The identification of intermittent fasting as an alternative method to traditional weight maintenance protocols could have a significant impact on preventing body weight regain common after successful weight loss, and potentially lead to a reduction in pharmaceutical and clinical costs related to the care of overweight and obese adults. Type: Interventional Start Date: Mar 2021 |
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Secondary Progressive
All males and females between 18-70 years of age regardless of their race and ethnicity with
a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive
Multiple Sclerosis (SPMS), and Relapse Remitting Multiple Sclerosis (RRMS) are invited to... expand
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse Remitting Multiple Sclerosis (RRMS) are invited to participate in this Observational study being conducted across four sites in the US. Since this is an observational study no medication/drug or treatment will be given to the participants. The investigator will be collecting information about the participant's MS disease, its progression, current medications, radiographic scans, and blood samples. This will help the investigator evaluate the biomarkers and new treatment options to better understand the MS disease process. Type: Observational Start Date: Mar 2023 |
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical...
SpineX Inc.
Neurogenic Bladder
Spinal Cord Injuries (Complete and Incomplete)
Stroke
Multiple Sclerosis
The purpose of this study is to evaluate the effectiveness and safety of SCONE
neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in
improving symptoms of Neurogenic Lower Urinary Tract Dysfunction
expand
The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction Type: Interventional Start Date: May 2022 |
Social Risk Factors and Discrimination in Cancer Survivorship
Medstar Health Research Institute
Social Determinants of Health
Breast Cancer
Prostate Cancer
Health Equity
Disparities
The objective of the proposed study is to scale social risk factor screening and referral for
cancer survivors and to solidify information exchange between clinical and community settings
in order to improve survivor health and well-being. This will be completed through three... expand
The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community settings in order to improve survivor health and well-being. This will be completed through three primary aims: 1) To ascertain workflow and map community resources needed to facilitate social risk factor screening and referral for breast and prostate cancer survivors in Washington, District of Columbia. 2) To determine impact of Community Health Worker (CHW) support on Black breast and prostate cancer survivor health and wellbeing as measured through quality of life (QOL) and social connection. 3) To determine impact of anti-racism training for staff and clinicians at three cancer centers on patient-reported discrimination. Type: Interventional Start Date: May 2022 |
Phase IB/II of CPX-351 for Relapse Prevention in AML
Georgetown University
Acute Myeloid Leukemia (AML) in Remission
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will
continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient
remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days
pending toxicity.... expand
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity. The maximum tolerated dose will be used for the phase II expansion portion of the study. Type: Interventional Start Date: May 2023 |
Study of Kidney Tumors in Younger Patients
Children's Oncology Group
Adult Cystic Nephroma
Anaplastic Kidney Wilms Tumor
Angiolipoma
Cellular Congenital Mesoblastic Nephroma
Classic Congenital Mesoblastic Nephroma
This research trial studies kidney tumors in younger patients. Collecting and storing samples
of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may
help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify... expand
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. Type: Observational Start Date: Feb 2006 |
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield...
Mercator MedSystems, Inc.
Thrombosis, Deep Vein
Iliofemoral; Thrombosis
This is a study of a medical procedure that utilizes a commercially available catheter (the
Bullfrog® Micro-Infusion Device) to locally deliver a commercially available
anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after
DVT recanalization,... expand
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure. Type: Interventional Start Date: Oct 2021 |
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove...
SWOG Cancer Research Network
Metastatic Clear Cell Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8
This phase III trial compares the effect of adding surgery to a standard of care
immunotherapy-based drug combination versus a standard of care immunotherapy-based drug
combination alone in treating patients with kidney cancer that has spread to other places in
the body (metastatic).... expand
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer. Type: Interventional Start Date: Mar 2021 |
Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus
Medstar Health Research Institute
Vulvar Lichen Sclerosus
This is a randomized placebo-controlled trial design to determine whether combining
FxCO2-laser with the traditional therapy of clobetasol propionate 0.05% ointment (combined
treatment) as compared to FxCO2-laser and placebo ointment (FxCO2-laser only) will improve
treatment... expand
This is a randomized placebo-controlled trial design to determine whether combining FxCO2-laser with the traditional therapy of clobetasol propionate 0.05% ointment (combined treatment) as compared to FxCO2-laser and placebo ointment (FxCO2-laser only) will improve treatment response in women undergoing FxCO2-laser for vulvar lichen sclerosus. Primary objective: To evaluate if women with LS who undergo FxCO2 laser therapy and concomitant TCS (clobetasol group) have higher treatment success (defined as a MCID of a ≥16 point improvement in Skindex-29 questionnaire) than those who undergo FxCO2 laser and placebo ointment (placebo group). - Hypothesis: A higher proportion of women randomized to clobetasol will achieve treatment success as compared to those randomized to placebo. - Approach: The proportion of women in each cohort who obtain a ≥16 point improvement in Skindex-29 validated questionnaire score from baseline to final visit will be compared. Secondary objectives: To compare change in pre- and post-treatment scores on validated questionnaires measuring vulvovaginal symptoms, sexual function, lower urinary tract function, and genital self-image between the clobetasol group compared to the placebo group. - Hypothesis: Women randomized to clobetasol will demonstrate an equal or greater improvement on validated quality of life questionnaires measuring vulvovaginal symptoms, sexual function, lower urinary tract function, and genital self-image as compared to women randomized to placebo. - Approach: Change scores will be calculated to determine change per participant over the treatment period and mean change scores will be compared between cohorts. Type: Interventional Start Date: Mar 2022 |
Thoraflex Hybrid and Relay Extension Post-Approval Study
Vascutek Ltd.
Thoracic Diseases
Aortic Aneurysm
Aortic Dissection
Thoracic Aortic Aneurysm
Thoracic Aortic Dissection
The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in
combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting
the aortic arch and descending aorta with or without involvement of the ascending aorta.... expand
The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting the aortic arch and descending aorta with or without involvement of the ascending aorta. Patients who undergo treatment with the Thoraflex Hybrid device with or without extension with a RelayPro NBS stent-graft will be eligible for enrolment and study activities and follow-up regime will follow standard care at each participating site. Participant involvement in the study will last for a total of 10 years from the point at which the Thoraflex Hybrid device is placed. Type: Observational Start Date: Mar 2023 |
Home-Based Exercise Tele-Rehabilitation After COVID-19
VA Office of Research and Development
Post SARS-CoV2 (COVID-19)
The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in catastrophic infections and
fatalities across the nation. Many older Veterans with comorbidities are especially
vulnerable to complications and poor recovery. This award will investigate the effect of a
novel,... expand
The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in catastrophic infections and fatalities across the nation. Many older Veterans with comorbidities are especially vulnerable to complications and poor recovery. This award will investigate the effect of a novel, home-based, supervised, group exercise tele-rehabilitation in Veterans recovered from COVID-19 on cardiopulmonary and physical function. Type: Interventional Start Date: Jun 2023 |
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage...
ECOG-ACRIN Cancer Research Group
Advanced Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Melanoma of Unknown Primary
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
This phase II trial investigates how well biomarkers on PET/CT imaging drive early
discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be
removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for
patients... expand
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy. Type: Interventional Start Date: Feb 2021 |
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
ECOG-ACRIN Cancer Research Group
Anal Basaloid Carcinoma
Anal Canal Cloacogenic Carcinoma
Anal Canal Squamous Cell Carcinoma
Anal Margin Squamous Cell Carcinoma
Stage I Anal Cancer AJCC v8
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation)
therapy works in comparison to standard-dose chemoradiation in treating patients with
early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and
capecitabine,... expand
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type. Type: Interventional Start Date: Jan 2020 |
EndoBarrier System Pivotal Trial(Rev E v2)
GI Dynamics
Diabetes type2
Obesity
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier
System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and
Obesity, the STEP-1 Study.
A multi-center, double-blinded, randomized, sham-controlled trial... expand
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the EndoBarrier System plus moderate intensity lifestyle and dietary counseling compliant with 2019 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (EndoBarrier):1 (Sham). Type: Interventional Start Date: Sep 2019 |
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
Georgetown University
Dementia With Lewy Bodies
Dementia with Lewy Bodies (DLB) is an alphasynucleinopathy and the second most common form of
dementia in the elderly. DLB shares striking neuropathological and clinical similarities with
both Parkinson's disease (PD) and Alzheimer's disease (AD). Nilotinib (Tasigna®, AMN107,... expand
Dementia with Lewy Bodies (DLB) is an alphasynucleinopathy and the second most common form of dementia in the elderly. DLB shares striking neuropathological and clinical similarities with both Parkinson's disease (PD) and Alzheimer's disease (AD). Nilotinib (Tasigna®, AMN107, Novartis, Switzerland) is approved by the FDA and is well tolerated for CML treatment at oral doses of 600-800mg daily. The Investigators propose to perform a phase II randomized, double blinded, placebo controlled study to evaluate the impact of Nilotinib in patients with DLB. Type: Interventional Start Date: Jul 2019 |
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors
Biofourmis Inc.
Heart Failure
The goal of this real-world, multi-center, randomized, outpatient study is to assess the
effectiveness of the Biofourmis cloud based BiovitalsHFTM platform to recommend optimal
titration of Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced
ejection fraction... expand
The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHFTM platform to recommend optimal titration of Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) subjects. Type: Interventional Start Date: Jan 2020 |
Improving Genetic Counseling for BRCA+ Mothers
Georgetown University
Breast Cancer
Genetic counseling and testing for hereditary breast cancer may reveal that you, and possibly
your blood relatives, are at increased risk for the disease across the lifespan. This
includes biological children, both male and female. We do not yet know the best ways to
educate... expand
Genetic counseling and testing for hereditary breast cancer may reveal that you, and possibly your blood relatives, are at increased risk for the disease across the lifespan. This includes biological children, both male and female. We do not yet know the best ways to educate mothers who have a risk gene (are BRCA+) about whether, when, and how to share genetic information with their children or manage their thoughts and feelings. The purpose of this study is to help mothers make more informed choices about talking with children about hereditary breast cancer, provide them with age-and gender-appropriate information and emotional support, and improve their psychological well-being. Type: Interventional Start Date: Jul 2020 |
The EMPOWER Study: Endometriosis Diagnosis Using microRNA
Dot Laboratories, Inc.
Endometriosis
Endometriosis is a complex, heterogeneous disease that may present inconsistently across
women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a
biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective,... expand
Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal risk study in women undergoing laparoscopy, laparotomy or other pelvic surgical procedure for endometriosis, infertility or another benign gynecological indication. Participants will undergo 2 study visits for collection of blood and saliva and completion of study questionnaires. Type: Observational Start Date: Nov 2020 |
Exercise and Brain Health
Baltimore VA Medical Center
Stroke
Cardiovascular Risk Factors
Transient Ischemic Attack (TIA)
The risk of stroke and vascular dementia is high in individuals who have had a prior stroke
or TIA, and in those who have vascular disease risk factors, such as high blood pressure,
abnormal cholesterol, diabetes or pre-diabetes. These vascular risk factors can improve with... expand
The risk of stroke and vascular dementia is high in individuals who have had a prior stroke or TIA, and in those who have vascular disease risk factors, such as high blood pressure, abnormal cholesterol, diabetes or pre-diabetes. These vascular risk factors can improve with exercise. This study will examine the impact of a 6 month, low intensity group exercise class on fitness, walking, balance, and brain health. This study will also collect fitness, walking, balance, and brain health outcome measures at baseline and post all other MERCE exercise and robotics interventions. Type: Interventional Start Date: Jul 2013 |
- Previous
- Next